DOCSLIB.ORG

Get High-Res Image

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Get High-Res Image 50 40 30 20 10 226 155 243 73 63 51 # mutations Non syn. Syn. *CpG->T *Cp(A/C/T)->T A->G transver indel+null double_null # mutations/"< 0 10 15 20 25 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 0% 0% 1% 2% 1% 1% 1% 1% 0% 1% 1% 4% 1% 1% 1% 2% 0% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 2% 1% 1% 1% 1% 1% 0% 1% 1% 1% 1% 2% 1% 1% 3% 1% 1% 1% 1% 2% 1% 1% 1% 2% 1% 1% 2% 1% 1% 1% 1% 1% 2% 1% 1% 1% 1% 1% 2% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 2% 1% 1% 5% 1% 1% 1% 2% 1% 1% 1% 1% 1% 2% 1% 1% 1% 1% 1% 1% 2% 2% 1% 2% 2% 13% 2% 4% 4% 9% 4% 19% 0% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 3% 3% 3% 4% 5% 29% 0 5 %IRC-A$'3778'TP %IRC-C3'5677-TP%IRC'(0'4710'TP%IRC-A3'3383'TP %IRC-E.'5907-TP%IRC-A3'3382'TP%IRC'(0'4712'TP %IRC-A3'3372'TP%IRC-A3'3316'TP%IRC-A%'3444'TP %IRC-C*'59,2-TP%IRC-A3'3378'TP%IRC-A3'3308'TP %IRC'(P'5184'TP%IRC'(0'5693'TP%IRC'(,'5159'TP %IRC'(P'4968'TP%IRC'(P'5196'TP%IRC-C3'5675-TP %IRC-C--55,0-TP%IRC'(P'5169'TP%IRC'(0'5699'TP %IRC-C3'5676-TP%IRC'(P'5198'TP%IRC-C3'56,4-TP %IRC-A3'3331'TP%IRC'(0'5399'TP%IRC-C*'5470-TP %IRC'(0'4706'TP%IRC'(0'4,16'TP%IRC'(P'4159'TP %IRC'(P'5183'TP%IRC'(0'5703'TP%IRC'(P'5187'TP %IRC'(,'4148'TP%IRC-C*'5460-TP%IRC'(P'4164'TP %IRC'(0'5085'TP%IRC-C3'4903-TP%IRC-C3'4634-TP %IRC'(4'5,32'TP%IRC'(4'5,36'TP%IRC'(P'49,,'TP %IRC'(P'4960'TP%IRC'(0'5696'TP%IRC-C3'5679-TP %IRC'(0'5115'TP%IRC'(P'4989'TP%IRC-C*'5465-TP %IRC'(P'4999'TP%IRC'(P'5181'TP%IRC'(P'5200'TP %IRC'(P'4964'TP%IRC'(0'5705'TP%IRC'(,'4154'TP %IRC-C3'4920-TP%IRC-C*'5466-TP%IRC-C3'6030-TP %IRC'(0'5710'TP%IRC-C3'4912-TP%IRC'(0'5711'TP %IRC-C3'4,75-TP%IRC'(P'4982'TP%IRC'(0'5116'TP %IRC'(0'5110'TP%IRC'(0'4,18'TP%IRC-C*'4,53-TP %IRC'(P'4329'TP%IRC'(P'4341'TP%IRC'(0'5104'TP %IRC-C*'59,9-TP%IRC'(P'4995'TP%IRC-A3'3373'TP %IRC-C*'5455-TP%IRC-A%'3458'TP%IRC'(P'5180'TP %IRC'(,'4621'TP%IRC'(P'4975'TP%IRC-C3'490,-TP %IRC-A%'3455'TP%IRC'(P'4161'TP%IRC'(P'5199'TP %IRC-C--5591-TP%IRC'(0'5402'TP%IRC-C*'4,61-TP %IRC-C*'5469-TP%IRC'(,'4151'TP%IRC'(0'5081'TP %IRP'AL-3473'TP%IRC'(0'4,27'TP%IRC'(0'5097'TP %IRC-C--55,1-TP%IRC'(P'5174'TP%IRC'(0'5075'TP %IRC'(0'5106'TP%IRC'(0'5108'TP%IRC-A%'3430'TP %IRC-A%'3451'TP%IRC'(P'5190'TP%IRC'(0'5077'TP %IRC-C3'4644-TP%IRC-C*'5457-TP%IRC'(,'5163'TP %IRC-C3'4637-TP%IRC'(0'5709'TP%ICH'%&',432-TP %IRC'(,'5162'TP%IRC'(,'5550'TP%IRC'(,'5551'TP %IRC-C--55,,-TP%IRC'(2'5635'TP%IRC'(2'3924'TP %IRC'(0'4,47'TP%IRC'(P'4167'TP%IRC-C*'59,5-TP %IRC-C*'59,4-TP%IRC'(P'4965'TP%IRC'(,'4153'TP %IRC'(P'5007'TP%IRC'(P'4963'TP%IRC'(P'5175'TP %IRC'(0'5691'TP%IRC-C3'6027-TP%IRC'(0'4,10'TP %IRC'(P'5001'TP%IRC-C*'59,7-TP%IRC'(P'5176'TP %IRC-C3'4,94-TP%IRP'(2-5,92'TP%IRC-C3'6033-TP %IRC'(P'4992'TP%IRC-C3'491,-TP%IRC'(P'4977'TP %IRC'(P'5006'TP%IRC-C3'4916-TP%IRC'(0'4,23'TP %IRC-C3'56,6-TP%IRC'(0'4945'TP%IRC'(P'4998'TP %IRC-C--6093-TP%IRC-C--6090-TP%IRC-E.'5904-TP %IRC'(P'5192'TP%IRC'(P'4991'TP%IRC'(P'4986'TP %IRC'(P'5173'TP%IRC-C3'5672-TP%IRC'(P'4976'TP %IRC'(P'4967'TP%IRC'(,'5549'TP%IRC'(,'5164'TP %IRC-C3'463,-TP%IRC'(0'5692'TP%IRC'(0'5695'TP %IRC-A3'3385'TP%IRC'(0'5099'TP%IRC-C3'4900-TP %IRC-E.'5905-TP%IRC'(P'4,07'TP%IRC-E.'5906-TP %IRC'(0'50,,'TP%IRC'(P'5195'TP%IRC'(0'5107'TP %IRC-C3'6031-TP%IRC'(4'5,43'TP%IRC-C3'4636-TP %IRP'-&'A9!9-TP%IRC-C3'56,0-TP%IRC'(0'5102'TP %IRC'(P'5009'TP%IRC-C3'6032-TP%IRC'(P'5004'TP %IRC'(0'5,12'TP%IRC'(P'5177'TP%IRC'(P'4162'TP %IRC'(P'5008'TP%IRC-A3'3349'TP%IRC'(P'4961'TP %IRC'(P'4974'TP%IRC-C*'545,-TP%IRC'(P'4771'TP %IRC-C--55,3-TP%IRC-C*'4,5,-TP%IRC'(P'5194'TP %IRC'(0'4713'TP%IRC'(P'4765'TP%IRC'(P'4355'TP %IRC'(P'4166'TP%IRC'(0'4703'TP%IRC-A%'3445'TP %IRC'(P'4789'TP%IRC'(0'4,33'TP%IRC'(P'4798'TP %IRC-C3'4,,5-TP%IRC-C3'4,,4-TP%IRC-C3'4,72-TP %IRC'(0'4,24'TP%IRC'(P'4762'TP%IRC'(0'4690'TP %IRC-C3'4,92-TP%IRC'(0'4,22'TP%IRC'(0'4714'TP %IRC'(P'4340'TP%IRC'(P'4763'TP%IRC'(0'4,45'TP %IRC'(0'5098'TP%IRC'(P'4342'TP%IRC'(P'4759'TP %ICH'%&',434-TP%ICH'%L',329'TP%ICH'%O',414'TP %ICH'%&',436-TP%ICH'%&',431-TP%ICH'%O',403'TP %IRC-A3'3313'TP%ICH'%O',416'TP%IRC-C*'5463-TP %IRC-A3'3363'TP%IRC-A%'3440'TP%ICH'%&',42,-TP %IRC'(P'4176'TP%IRP'A4-A57E'TP%IRC-A3'3346'TP %ICH'%O',408'TP%ICH'%L',336'TP%IRP'5P-A9%3'TP %ICH'%L',339'TP%ICH'%O',413'TP%ICH'%L',337'TP %ICH'%&',41,-TP%ICH'%&',424-TP%ICH'%L',341'TP %IRP'(1-A655'TP%IRP'(2-5,,1'TP%ICH'%L',338'TP %IRP'(3-4104'TP%ICH'%L',324'TP%IRP'(2-5,93'TP %IRC'(0'5117'TP%IRC-C*'4,65-TP%ICH'%&',423-TP %IRP'5P-A9%H'TP%IRC'(0'5096'TP%ICH'%&',430-TP %IRP'P4-A5E7'TP%ICH'%O',415'TP%IRC-A%'3425'TP %ICH'%O',409'TP%ICH'%&',433-TP%ICH'%"',43,-TP %ICH'%&',421-TP%ICH'%L',325'TP%ICH'%&',427-TP %ICH'%&',429-TP%ICH'%L',330'TP%ICH'%&',435-TP %ICH'%O',411'TP%IRP'(9-A,1)'TP%ICH'%O',410'TP %IRP'"H'A561-TP%IRC-A3'3380'TP%ICH'%L',334'TP %IRP'!7-A,LE'TP%IRP'.*-A9P3-TP%IRP'IA'A,3W-TP %IRP'AL-7173'TP%IRP'5P-A9%A'TP%IRP')*',196'TP %IRP'4A-A93-'TP%IRC-C--60,7-TP%IRP'(2-7059'TP %IRP'(2-5,,2'TP%IRP'(1-7332'TP%IRP' *-6132'TP %IRP'$#-A7$2'TP%IRP'!L-A59R'TP%IRP'$#-A71$'TP %IRP'HE'A5&H-TP%IRP'AL-3472'TP%IRP'A4-7997'TP %IRP'IA'A40U-TP%IRC'(0'5707'TP%IRP'A4-7734'TP %IRC-A3'3374'TP%IRC-A%'3453'TP%IRP' *-6135'TP %IRC-A%'3465'TP%IRC-A%'3427'TP%IRC-A3'3319'TP %IRC-C3'56,2-TP%IRC-A3'3320'TP%IRC-A%'3447'TP %IRC-C*'59,6-TP%IRC-A3'3322'TP%IRC'(0'4,19'TP %IRC-A$'3777'TP%IRP'!7-7502'TP%IRC'(0'5095'TP %IRP'!L-A9%IRC-A3'3365'TP%IRC-A%'3443'TP E'TP %IRP'5P-A9%C'TP%IRP'V9-A7HT'TP%ICH'%L',332'TP %IRP'$#-A71.'TP%ICH'%L',344'TP%IRP'5P-A93*-TP %IRP'!7-A,L%IRP'(1-A656'TP%IRP'2*-A933-TP 'TP %IRP'!L-A9%IRP'.*-A9PL'TP%IRP'A4-A510'TP C-TP %IRP'5P-A93-'TP%IRP'2*-A93O-TP%IRP'IA'A,3T'TP %IRP'.*-A921'TP%IRC-A3'3323'TP%IRP'1,-A,$0'TP %IRP'P3-A,3.-TP%IRP'(2-705,'TP%IRC-C3'4,70-TP %IRP'%IRC'(0'5100'TP%IRP'EV-5903'TP *-6134'TP %IRP'(2-7050'TP%IRP'(1-539,'TP%IRP'(2-5,76'TP %IRP'(9-A44('TP%IRP'IA'A,3S'TP%IRP'(9-4617'TP %IRP'1,-A,94'TP%ICH'%L',333'TP%IRP'A4-A511'TP %IRP'%IRP'P4-A5E('TP%IRP'5P-A9%,'TP -'7,40-TP %IRP'%V-A6!E'TP%IRP'!L-A4E"'TP%IRC-C3'4640-TP %IRC'(P'5182'TP%IRC'(P'4347'TP%IRP'(2-5,7,'TP %IRP'.*-A9PR'TP%IRP'P4-A5E,'TP%IRC'(P'5168'TP %IRP'!7-A4T"'TP%IRC-C*'5456-TP%IRP'A4-A7.*'TP %IRC-C3'4905-TP%IRC-A%'3428'TP%IRP'1,-A,9,'TP %IRP'5P-A93.'TP%IRC'(0'4,52'TP%IRC-C3'4,71-TP %IRC-A3'3311'TP%IRC-A%'3431'TP%IRC-A3'3367'TP %IRC-C3'4923-TP%IRC-C3'567,-TP%IRC'(P'4774'TP %IRC'(0'5094'TP%IRC'(0'4,28'TP%IRC'(P'5189'TP %IRC-A%'3434'TP%IRC'(0'5698'TP%IRC'(0'4718'TP %IRC'(0'5694'TP%IRC-A%'3436'TP%IRC-A3'3387'TP %IRC-C3'4,,7-TP%IRC'(4'5,44'TP%IRC'(0'5712'TP %IRC'(P'4985'TP%IRC'(0'4,42'TP%IRC'(0'5713'TP %IRC'(2'4099'TP%IRC-A3'3362'TP%IRC'(0'5120'TP %IRC-C*'4,54-TP%IRC'(P'4993'TP%IRC-C3'4913-TP %IRP'(2-5,90'TP%IRP'A4-75,3'TP%IRC-A%'3460'TP %IRC'(P'4158'TP%IRC'(0'4,15'TP%IRC-C3'4635-TP %IRC'(P'5170'TP%IRC'%IRC-A3'3326'TP V'5566-TP %IRC'(P'4973'TP%IRC'(P'5186'TP%IRC'(0'5113'TP %IRC-C*'5454-TP%IRC'(P'4987'TP%IRC'(0'4,49'TP %IRC'(0'4694'TP%IRC'(P'4351'TP%IRC-C3'4,,,-TP %IRC'(0'4,43'TP%IRP'(2-7051'TP%ICH'%L',345'TP %IRC'%IRP'(1-A657'TP%IRC'(P'5010'TP V'556,-TP %IRC'(,'5158'TP%IRP'A4-7996'TP%IRC'(P'4326'TP %IRC'(P'4345'TP%IRP'1,-A,97'TP%ICH'%L',323'TP %IRC'(,'4622'TP%IRC'(0'4,37'TP%IRP'(2-5,77'TP %IRP'$#-A7$"'TP%IRP'(2-5,75'TP%IRC'(,'4620'TP %IRC-C*'5461-TP%IRC'(P'5178'TP%IRP'4A-A93#'TP %IRC'(0'5121'TP%IRC-C*'5459-TP%IRC'(0'4,14'TP %IRC'(4'5,35'TP%IRP'(9-5155'TP%IRP'A4',09,'TP %IRP'2*-A93L-TP%IRC'(0'4,11'TP%IRC-C3'5671-TP %IRC'(2'4101'TP%IRC'(P'4983'TP%IRP'(2-7061'TP %IRC-C3'4,91-TP%IRP'(2-5,91'TP%IRC'(P'4790'TP %IRP'.*-A9P%'TP%IRP'2*-A93%-TP%IRC-C*'4,66-TP %IRC'(0'5092'TP%IRC-C3'4,69-TP%IRC'(P'4352'TP %IRC-C--6097-TP%IRC-C3'4641-TP%IRC-A3'3317'TP %IRP'2*-A93%IRC'(0'4691'TP%IRC'(P'4163'TP -TP %IRP'1,-A,R*'TP%IRC'(,'4143'TP%IRC'(4'5,38'TP %IRP'"H'A560-TP%IRC'(2'5641'TP%IRC-C*'5452-TP %IRC'(P'5000'TP%IRC'(0'4,44'TP%IRC-C*'5467-TP %IRC-C3'56,3-TP%IRC-C3'56,1-TP%IRC'(P'5202'TP %IRP'HE'A5&L-TP%IRP'$#-A71V'TP%IRP'$#-A7$L'TP %IRP'(9-A5-,'TP%ICH'%L',328'TP%IRP'%V-A74V'TP %ICH'%O',404'TP%ICH'%"',440-TP%ICH'%"',476-TP %IRC'(0'5701'TP%ICH'%L',335'TP%IRC' V'5574-TP %ICH'%L',331'TP%IRC-A%'3429'TP%ICH'%&',437-TP %ICH'%L',346'TP%ICH'%L',340'TP%IRP'2*-A931-TP %ICH'%"',442-TP%ICH'%&',426-TP%ICH'%O',405'TP %IRP'(9-A69E'TP%ICH'%O',406'TP%ICH'%O',407'TP %IRP'5P-A9%2'TP%IRC'(P'4770'TP%IRP'2*-A93I-TP %IRP'.*-A9P$'TP%IRC-C3'4639-TP%IRP'2*-A932-TP %IRP'A4-A6HP'TP%ICH'%L',343'TP%IRC-C*'5462-TP %IRP'2*-A936-TP%IRC'(P'4338'TP%IRC'(0'5083'TP %ICH'%"',439-TP%ICH'%O',417'TP%IRP'(1-A47&'TP %IRP'(1-A47"'TP%IRC-C3'4901-TP%IRC'(,'5546'TP %IRP'EV-5902'TP%IRP'1,-A,96'TP%IRC'(0'5084'TP %IRC'(P'4768'TP%IRC'(2'4098'TP%IRP'(2-7044'TP %IRP'.*-A9P*-TP%ICH'%&',419-TP%IRP'37-A,I2'TP %IRP'$#-A7$.'TP%IRP'5P-A93V-TP%IRC-C*'4,62-TP %IRC'(0'4693'TP%IRC-C3'4,,9-TP%IRC'(,'5545'TP %IRP'!L',500'TP%IRC-C3'4902-TP%IRP'5P-A931-TP %IRP'(2-5,,5'TP%IRC-C3'4,99-TP%IRP'A4-7915'TP %IRC-C3'4,76-TP%IRP'2*-A932-TP%IRP'P4-A5E6'TP %IRP'"H'A,54-TP%IRP'2*-A93&-TP%IRP'2*-A93,-TP %IRP'A4',312'TP%IRP'(2-5,,3'TP%IRC'(0'5400'TP %IRC'(0'5702'TP%IRP'2*-A93!-TP%IRC-A3'3358'TP %IRP'(2-5,,6'TP%IRP'A4-75,4'TP%IRP'A4-72,6'TP %IRC'(0'5119'TP%IRC-C*'4,57-TP%IRC'(0'5697'TP %ICH'%"',441-TP%IRC'(0'4,46'TP%IRC-C3'4907-TP %IRP'"H'A,57-TP%IRP'A4-7,2,'TP%IRC-A3'3347'TP %IRC'(P'4160'TP%IRC-C3'4,73-TP%IRP'+9-A97!-TP %IRP'!7-6797'TP%IRC-C3'4,,6-TP%IRC-A3'3357'TP %IRP'!L-7773'TP%IRC'(0'5706'TP%ICH'%L',326'TP %IRP'37',537-TP%IRC'(P'4169'TP%IRP'(3-3925'TP %IRP'%IRC'(P'4795'TP -'7,36-TP-'7,41-TP %IRP'$#-A7$R'TP%IRP'A4-A4,%IRC'(P'4331'TP 'TP %IRP'A4',310'TP%IRP'%IRP')*',195'TP *-6133'TP %IRP'"H'A55*'TP%IRP'2*-A93E-TP%IRP'(2-7046'TP %IRP'"H'A562-TP%IRP'2*-A93$-TP%IRP'A4-A4*T-TP %IRC'%IRC'(P'4970'TP%IRC'(P'4787'TP V'5576-TP %IRP'IA'A40Y'TP%IRP'!L-A59T-TP%IRP'HE'7130'TP %IRC'(P'4,01'TP%IRC'(P'5201'TP%IRP'(2-5,,9'TP
Load more

Recommended publications
  • Investigating the Genetic Basis of Cisplatin-Induced Ototoxicity in Adult South African Patients
    --------------------------------------------------------------------------- Investigating the genetic basis of cisplatin-induced ototoxicity in adult South African patients --------------------------------------------------------------------------- by Timothy Francis Spracklen SPRTIM002 SUBMITTED TO THE UNIVERSITY OF CAPE TOWN In fulfilment of the requirements for the degree MSc(Med) Faculty of Health Sciences UNIVERSITY OF CAPE TOWN University18 December of Cape 2015 Town Supervisor: Prof. Rajkumar S Ramesar Co-supervisor: Ms A Alvera Vorster Division of Human Genetics, Department of Pathology, University of Cape Town 1 The copyright of this thesis vests in the author. No quotation from it or information derived from it is to be published without full acknowledgement of the source. The thesis is to be used for private study or non- commercial research purposes only. Published by the University of Cape Town (UCT) in terms of the non-exclusive license granted to UCT by the author. University of Cape Town Declaration I, Timothy Spracklen, hereby declare that the work on which this dissertation/thesis is based is my original work (except where acknowledgements indicate otherwise) and that neither the whole work nor any part of it has been, is being, or is to be submitted for another degree in this or any other university. I empower the university to reproduce for the purpose of research either the whole or any portion of the contents in any manner whatsoever. Signature: Date: 18 December 2015 ' 2 Contents Abbreviations ………………………………………………………………………………….. 1 List of figures …………………………………………………………………………………... 6 List of tables ………………………………………………………………………………….... 7 Abstract ………………………………………………………………………………………… 10 1. Introduction …………………………………………………………………………………. 11 1.1 Cancer …………………………………………………………………………….. 11 1.2 Adverse drug reactions ………………………………………………………….. 12 1.3 Cisplatin …………………………………………………………………………… 12 1.3.1 Cisplatin’s mechanism of action ……………………………………………… 13 1.3.2 Adverse reactions to cisplatin therapy ……………………………………….
    [Show full text]
  • Chr CNV Start CNV Stop Gene Gene Feature 1 37261312 37269719
    chr CNV start CNV stop Gene Gene feature 1 37261312 37269719 Tmem131 closest upstream gene 1 37261312 37269719 Cnga3 closest downstream gene 1 41160869 41180390 Tmem182 closest upstream gene 1 41160869 41180390 2610017I09Rik closest downstream gene 1 66835123 66839616 1110028C15Rik in region 2 88714200 88719211 Olfr1206 closest upstream gene 2 88714200 88719211 Olfr1208 closest downstream gene 2 154840037 154846228 a in region 3 30065831 30417157 Mecom closest upstream gene 3 30065831 30417157 Arpm1 closest downstream gene 3 35476875 35495913 Sox2ot closest upstream gene 3 35476875 35495913 Atp11b closest downstream gene 3 39563408 39598697 Fat4 closest upstream gene 3 39563408 39598697 Intu closest downstream gene 3 94246481 94410611 Celf3 in region 3 94246481 94410611 Mrpl9 in region 3 94246481 94410611 Riiad1 in region 3 94246481 94410611 Snx27 in region 3 104311901 104319916 Lrig2 in region 3 144613709 144619149 Clca6 in region 3 144613709 144619149 Clca6 in region 4 108673 137301 Vmn1r2 closest downstream gene 4 3353037 5882883 6330407A03Rik in region 4 3353037 5882883 Chchd7 in region 4 3353037 5882883 Fam110b in region 4 3353037 5882883 Impad1 in region 4 3353037 5882883 Lyn in region 4 3353037 5882883 Mos in region 4 3353037 5882883 Penk in region 4 3353037 5882883 Plag1 in region 4 3353037 5882883 Rps20 in region 4 3353037 5882883 Sdr16c5 in region 4 3353037 5882883 Sdr16c6 in region 4 3353037 5882883 Tgs1 in region 4 3353037 5882883 Tmem68 in region 4 5919294 6304249 Cyp7a1 in region 4 5919294 6304249 Sdcbp in region 4 5919294
    [Show full text]
  • The Hypothalamus As a Hub for SARS-Cov-2 Brain Infection and Pathogenesis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.08.139329; this version posted June 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. The hypothalamus as a hub for SARS-CoV-2 brain infection and pathogenesis Sreekala Nampoothiri1,2#, Florent Sauve1,2#, Gaëtan Ternier1,2ƒ, Daniela Fernandois1,2 ƒ, Caio Coelho1,2, Monica ImBernon1,2, Eleonora Deligia1,2, Romain PerBet1, Vincent Florent1,2,3, Marc Baroncini1,2, Florence Pasquier1,4, François Trottein5, Claude-Alain Maurage1,2, Virginie Mattot1,2‡, Paolo GiacoBini1,2‡, S. Rasika1,2‡*, Vincent Prevot1,2‡* 1 Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, DistAlz, UMR-S 1172, Lille, France 2 LaBoratorY of Development and PlasticitY of the Neuroendocrine Brain, FHU 1000 daYs for health, EGID, School of Medicine, Lille, France 3 Nutrition, Arras General Hospital, Arras, France 4 Centre mémoire ressources et recherche, CHU Lille, LiCEND, Lille, France 5 Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and ImmunitY of Lille (CIIL), Lille, France. # and ƒ These authors contriButed equallY to this work. ‡ These authors directed this work *Correspondence to: [email protected] and [email protected] Short title: Covid-19: the hypothalamic hypothesis 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.06.08.139329; this version posted June 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Amino Acid Sequences Directed Against Cxcr4 And
    (19) TZZ ¥¥_T (11) EP 2 285 833 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07K 16/28 (2006.01) A61K 39/395 (2006.01) 17.12.2014 Bulletin 2014/51 A61P 31/18 (2006.01) A61P 35/00 (2006.01) (21) Application number: 09745851.7 (86) International application number: PCT/EP2009/056026 (22) Date of filing: 18.05.2009 (87) International publication number: WO 2009/138519 (19.11.2009 Gazette 2009/47) (54) AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME GEGEN CXCR4 UND ANDERE GPCR GERICHTETE AMINOSÄURESEQUENZEN SOWIE VERBINDUNGEN DAMIT SÉQUENCES D’ACIDES AMINÉS DIRIGÉES CONTRE CXCR4 ET AUTRES GPCR ET COMPOSÉS RENFERMANT CES DERNIÈRES (84) Designated Contracting States: (74) Representative: Hoffmann Eitle AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Patent- und Rechtsanwälte PartmbB HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL Arabellastraße 30 PT RO SE SI SK TR 81925 München (DE) (30) Priority: 16.05.2008 US 53847 P (56) References cited: 02.10.2008 US 102142 P EP-A- 1 316 801 WO-A-99/50461 WO-A-03/050531 WO-A-03/066830 (43) Date of publication of application: WO-A-2006/089141 WO-A-2007/051063 23.02.2011 Bulletin 2011/08 • VADAY GAYLE G ET AL: "CXCR4 and CXCL12 (73) Proprietor: Ablynx N.V. (SDF-1) in prostate cancer: inhibitory effects of 9052 Ghent-Zwijnaarde (BE) human single chain Fv antibodies" CLINICAL CANCER RESEARCH, THE AMERICAN (72) Inventors: ASSOCIATION FOR CANCER RESEARCH, US, • BLANCHETOT, Christophe vol.10, no.
    [Show full text]
  • Mean Depth 1000 More Than100×
    A B ×20 ×50 ×100 100% 1000 800 90% 600 80% 400 Mean depth 70% 200 0 60% 50% Mean coverage 40% PBL002_T PBL003_T PBL004_T PBL005_T PBL006_T PBL007_T PBL008_T PBL009_T PBL010_T PBL001_P 30% 20% 10% 0% PBL002_T PBL003_T PBL004_T PBL005_T PBL006_T PBL007_T PBL008_T PBL009_T PBL010_T PBL001_P Figure S1. Depths and coverages of targeted deep sequencing. A. Depths of targeted deep sequencing on 10 PBL cases (mean depth = 677). B. Coverages of the targeted sequences analyzed at the indicated depths; 98.8% of the targeted regions were sequenced at a depth more than 100×. A B ×2 ×10 ×20 250 100% 200 90% 150 80% 100 Mean depth 50 70% 0 60% 50% PBL002_T PBL004_T PBL007_T PBL008_T PBL010_T PBL001_P PBL001_N PBL002_N PBL004_N PBL007_N PBL008_N PBL010_N PBL001_M1 PBL001_M2 PBL001_M3 PBL001_M4 PBL001_M5 PBL001_M6 Mean coverage 40% 30% 20% 10% 0% PBL002_T PBL004_T PBL007_T PBL008_T PBL010_T PBL001_P PBL001_N PBL002_N PBL004_N PBL007_N PBL008_N PBL010_N PBL001_M1 PBL001_M2 PBL001_M3 PBL001_M4 PBL001_M5 PBL001_M6 C D 14 80 12 70 10 60 50 8 40 6 30 4 Number of mutations Number of mutations 20 2 10 0 0 PBL002_T PBL004_T PBL007_T PBL008_T PBL010_T PBL001_P PBL001_P PBL001_M1 PBL001_M2 PBL001_M3 PBL001_M4 PBL001_M5 PBL001_M6 Nonsynonymous SNV Stopgain SNV Nonframeshift indels Frameshift indels Splice site Figure S2. Sequencing coverages and numbers of mutations detected by WES. A. Depths of WES on tumor and normal DNA samples from 6 cases (mean depth = 124 for tumor samples and 141 for normal samples). B. Coverages of the exome sequences; 97.5% of the exome sequences were analyzed at a depth more than 20×. C-D.
    [Show full text]
  • Supplementary Data
    SUPPLEMENTARY METHODS 1) Characterisation of OCCC cell line gene expression profiles using Prediction Analysis for Microarrays (PAM) The ovarian cancer dataset from Hendrix et al (25) was used to predict the phenotypes of the cell lines used in this study. Hendrix et al (25) analysed a series of 103 ovarian samples using the Affymetrix U133A array platform (GEO: GSE6008). This dataset comprises clear cell (n=8), endometrioid (n=37), mucinous (n=13) and serous epithelial (n=41) primary ovarian carcinomas and samples from 4 normal ovaries. To build the predictor, the Prediction Analysis of Microarrays (PAM) package in R environment was employed (http://rss.acs.unt.edu/Rdoc/library/pamr/html/00Index.html). When more than one probe described the expression of a given gene, we used the probe with the highest median absolute deviation across the samples. The dataset from Hendrix et al. (25) and the dataset of OCCC cell lines described in this manuscript were then overlaid on the basis of 11536 common unique HGNC gene symbols. Only the 99 primary ovarian cancers samples and the four normal ovary samples were used to build the predictor. Following leave one out cross-validation, a predictor based upon 126 genes was able to identify correctly the four distinct phenotypes of primary ovarian tumour samples with a misclassification rate of 18.3%. This predictor was subsequently applied to the expression data from the 12 OCCC cell lines to determine the likeliest phenotype of the OCCC cell lines compared to primary ovarian cancers. Posterior probabilities were estimated for each cell line in comparison to the following phenotypes: clear cell, endometrioid, mucinous and serous epithelial.
    [Show full text]
  • Us 2018 / 0305689 A1
    US 20180305689A1 ( 19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 /0305689 A1 Sætrom et al. ( 43 ) Pub . Date: Oct. 25 , 2018 ( 54 ) SARNA COMPOSITIONS AND METHODS OF plication No . 62 /150 , 895 , filed on Apr. 22 , 2015 , USE provisional application No . 62/ 150 ,904 , filed on Apr. 22 , 2015 , provisional application No. 62 / 150 , 908 , (71 ) Applicant: MINA THERAPEUTICS LIMITED , filed on Apr. 22 , 2015 , provisional application No. LONDON (GB ) 62 / 150 , 900 , filed on Apr. 22 , 2015 . (72 ) Inventors : Pål Sætrom , Trondheim (NO ) ; Endre Publication Classification Bakken Stovner , Trondheim (NO ) (51 ) Int . CI. C12N 15 / 113 (2006 .01 ) (21 ) Appl. No. : 15 /568 , 046 (52 ) U . S . CI. (22 ) PCT Filed : Apr. 21 , 2016 CPC .. .. .. C12N 15 / 113 ( 2013 .01 ) ; C12N 2310 / 34 ( 2013. 01 ) ; C12N 2310 /14 (2013 . 01 ) ; C12N ( 86 ) PCT No .: PCT/ GB2016 /051116 2310 / 11 (2013 .01 ) $ 371 ( c ) ( 1 ) , ( 2 ) Date : Oct . 20 , 2017 (57 ) ABSTRACT The invention relates to oligonucleotides , e . g . , saRNAS Related U . S . Application Data useful in upregulating the expression of a target gene and (60 ) Provisional application No . 62 / 150 ,892 , filed on Apr. therapeutic compositions comprising such oligonucleotides . 22 , 2015 , provisional application No . 62 / 150 ,893 , Methods of using the oligonucleotides and the therapeutic filed on Apr. 22 , 2015 , provisional application No . compositions are also provided . 62 / 150 ,897 , filed on Apr. 22 , 2015 , provisional ap Specification includes a Sequence Listing . SARNA sense strand (Fessenger 3 ' SARNA antisense strand (Guide ) Mathew, Si Target antisense RNA transcript, e . g . NAT Target Coding strand Gene Transcription start site ( T55 ) TY{ { ? ? Targeted Target transcript , e .
    [Show full text]
  • Comprehensive Genomic Analysis of Dietary Habits in UK Biobank Identifies Hundreds of Genetic Associations
    ARTICLE https://doi.org/10.1038/s41467-020-15193-0 OPEN Comprehensive genomic analysis of dietary habits in UK Biobank identifies hundreds of genetic associations ✉ Joanne B. Cole 1,2,3, Jose C. Florez1,2,4 & Joel N. Hirschhorn1,3,5 Unhealthful dietary habits are leading risk factors for life-altering diseases and mortality. Large-scale biobanks now enable genetic analysis of traits with modest heritability, such as 1234567890():,; diet. We perform a genomewide association on 85 single food intake and 85 principal component-derived dietary patterns from food frequency questionnaires in UK Biobank. We identify 814 associated loci, including olfactory receptor associations with fruit and tea intake; 136 associations are only identified using dietary patterns. Mendelian randomization suggests our top healthful dietary pattern driven by wholemeal vs. white bread consumption is causally influenced by factors correlated with education but is not strongly causal for coronary artery disease or type 2 diabetes. Overall, we demonstrate the value in complementary phenotyping approaches to complex dietary datasets, and the utility of genomic analysis to understand the relationships between diet and human health. 1 Programs in Metabolism and Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, USA. 2 Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA. 3 Division of Endocrinology and Center for Basic and Translational Obesity Research, Boston Children’s Hospital, Boston, MA,
    [Show full text]
  • MOL #82305 TITLE PAGE Title: Induced CYP3A4 Expression In
    Downloaded from molpharm.aspetjournals.org at ASPET Journals on September 28, 2021 1 This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted.
    [Show full text]
  • Explorations in Olfactory Receptor Structure and Function by Jianghai
    Explorations in Olfactory Receptor Structure and Function by Jianghai Ho Department of Neurobiology Duke University Date:_______________________ Approved: ___________________________ Hiroaki Matsunami, Supervisor ___________________________ Jorg Grandl, Chair ___________________________ Marc Caron ___________________________ Sid Simon ___________________________ [Committee Member Name] Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Neurobiology in the Graduate School of Duke University 2014 ABSTRACT Explorations in Olfactory Receptor Structure and Function by Jianghai Ho Department of Neurobiology Duke University Date:_______________________ Approved: ___________________________ Hiroaki Matsunami, Supervisor ___________________________ Jorg Grandl, Chair ___________________________ Marc Caron ___________________________ Sid Simon ___________________________ [Committee Member Name] An abstract of a dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Neurobiology in the Graduate School of Duke University 2014 Copyright by Jianghai Ho 2014 Abstract Olfaction is one of the most primitive of our senses, and the olfactory receptors that mediate this very important chemical sense comprise the largest family of genes in the mammalian genome. It is therefore surprising that we understand so little of how olfactory receptors work. In particular we have a poor idea of what chemicals are detected by most of the olfactory receptors in the genome, and for those receptors which we have paired with ligands, we know relatively little about how the structure of these ligands can either activate or inhibit the activation of these receptors. Furthermore the large repertoire of olfactory receptors, which belong to the G protein coupled receptor (GPCR) superfamily, can serve as a model to contribute to our broader understanding of GPCR-ligand binding, especially since GPCRs are important pharmaceutical targets.
    [Show full text]
  • Comparative Molecular Portraits of Human Unfertilized Oocytes And
    Int. J. Dev. Biol. 56: 789-797 (2012) doi: 10.1387/ijdb.120230ja www.intjdevbiol.com Comparative molecular portraits of human unfertilized oocytes and primordial germ cells at 10 weeks of gestation FERDINAND DIEDRICHS1, BARBARA MLODY1, PEGGY MATZ1, HEIKO FUCHS1,2, LUKAS CHAVEZ1, KATHARINA DREWS1 and JAMES ADJAYE*,1,2 1Department of Vertebrate Genomics, Molecular Embryology and Aging Group, Max Planck Institute for Molecular Genetics, Berlin, Germany and 2Institute for Stem Cell Research and Regenerative Medicine, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany ABSTRACT Primordial germ cells (PGCs) are precursors of gametes and share several features in common with pluripotent stem cells, such as alkaline phosphatase activity and the expression of pluripotency-associated genes such as OCT4 and NANOG. PGCs are able to differentiate into oocytes and spermatogonia and establish totipotency after fertilization. However, our knowledge of human germ cell development is still fragmentary. In this study, we have carried out genome- wide comparisons of the transcriptomes and molecular portraits of human male PGCs (mPGCs), female PGCs (fPGCs) and unfertilized oocytes. We detected 9210 genes showing elevated expression in fPGCs, 9184 in mPGCs and 9207 in oocytes, with 6342 of these expressed in common. As well as known germ cell-related genes such as BLIMP1/PRDM1, PIWIL2, VASA/DDX4, DAZL, STELLA/ DPPA3 and LIN28, we also identified 465 novel non-annotated genes with orthologs in the mouse. A plethora of olfactory receptor-encoding genes were detected in all samples, which would sug- gest their involvement not only in sperm chemotaxis, but also in the development of female germ cells and oocytes.
    [Show full text]
  • Online Supporting Information S2: Proteins in Each Negative Pathway
    Online Supporting Information S2: Proteins in each negative pathway Index Proteins ADO,ACTA1,DEGS2,EPHA3,EPHB4,EPHX2,EPOR,EREG,FTH1,GAD1,HTR6, IGF1R,KIR2DL4,NCR3,NME7,NOTCH1,OR10S1,OR2T33,OR56B4,OR7A10, Negative_1 OR8G1,PDGFC,PLCZ1,PROC,PRPS2,PTAFR,SGPP2,STMN1,VDAC3,ATP6V0 A1,MAPKAPK2 DCC,IDS,VTN,ACTN2,AKR1B10,CACNA1A,CHIA,DAAM2,FUT5,GCLM,GNAZ Negative_2 ,ITPA,NEU4,NTF3,OR10A3,PAPSS1,PARD3,PLOD1,RGS3,SCLY,SHC1,TN FRSF4,TP53 Negative_3 DAO,CACNA1D,HMGCS2,LAMB4,OR56A3,PRKCQ,SLC25A5 IL5,LHB,PGD,ADCY3,ALDH1A3,ATP13A2,BUB3,CD244,CYFIP2,EPHX2,F CER1G,FGD1,FGF4,FZD9,HSD17B7,IL6R,ITGAV,LEFTY1,LIPG,MAN1C1, Negative_4 MPDZ,PGM1,PGM3,PIGM,PLD1,PPP3CC,TBXAS1,TKTL2,TPH2,YWHAQ,PPP 1R12A HK2,MOS,TKT,TNN,B3GALT4,B3GAT3,CASP7,CDH1,CYFIP1,EFNA5,EXTL 1,FCGR3B,FGF20,GSTA5,GUK1,HSD3B7,ITGB4,MCM6,MYH3,NOD1,OR10H Negative_5 1,OR1C1,OR1E1,OR4C11,OR56A3,PPA1,PRKAA1,PRKAB2,RDH5,SLC27A1 ,SLC2A4,SMPD2,STK36,THBS1,SERPINC1 TNR,ATP5A1,CNGB1,CX3CL1,DEGS1,DNMT3B,EFNB2,FMO2,GUCY1B3,JAG Negative_6 2,LARS2,NUMB,PCCB,PGAM1,PLA2G1B,PLOD2,PRDX6,PRPS1,RFXANK FER,MVD,PAH,ACTC1,ADCY4,ADCY8,CBR3,CLDN16,CPT1A,DDOST,DDX56 ,DKK1,EFNB1,EPHA8,FCGR3A,GLS2,GSTM1,GZMB,HADHA,IL13RA2,KIR2 Negative_7 DS4,KLRK1,LAMB4,LGMN,MAGI1,NUDT2,OR13A1,OR1I1,OR4D11,OR4X2, OR6K2,OR8B4,OXCT1,PIK3R4,PPM1A,PRKAG3,SELP,SPHK2,SUCLG1,TAS 1R2,TAS1R3,THY1,TUBA1C,ZIC2,AASDHPPT,SERPIND1 MTR,ACAT2,ADCY2,ATP5D,BMPR1A,CACNA1E,CD38,CYP2A7,DDIT4,EXTL Negative_8 1,FCER1G,FGD3,FZD5,ITGAM,MAPK8,NR4A1,OR10V1,OR4F17,OR52D1,O R8J3,PLD1,PPA1,PSEN2,SKP1,TACR3,VNN1,CTNNBIP1 APAF1,APOA1,CARD11,CCDC6,CSF3R,CYP4F2,DAPK1,FLOT1,GSTM1,IL2
    [Show full text]